A compound with antifungal activity and its application

By developing the BET-HDAC dual-target inhibitor combined with fluconazole, the problems of poor efficacy and resistance of existing antifungal drugs on candidiasis are solved, and the high efficiency and low toxicity resistance of Candida albicans are achieved Fungal effect.

CN116284002BActive Publication Date: 2024-11-15THE NAVAL MEDICAL UNIV OF PLA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310121933.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-16
Publication Date
2024-11-15
Estimated Expiration
2043-02-16

AI Technical Summary

Technical Problem

The existing antifungal drugs have limited efficacy in the treatment of invasive candidiasis, especially due to the rapid development of fungal resistance, the insufficient killing effect of existing drugs such as fluconazole on fungi, resulting in treatment failure and drug resistance. Problem, and the lack of selectivity of existing HDAC inhibitors, there may be problems with toxicity to the host.

Method used

A BET-HDAC dual-target inhibitor was developed to selectively inhibit the HDACs of Candida albicans by structure-specific compounds, in combination with fluconazole, to enhance antifungal activity and reduce drug resistance.

Benefits of technology

The compound has strong inhibitory activity on both BET and HDAC, showing selectivity to fungi, significantly reducing the cytotoxicity to normal human cells, excellent synergistic antifungal activity, and can effectively inhibit the virulence factor of Candida and 形态转换,显著降低小鼠模型中的真菌负荷。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116284002B_ABST
    Figure CN116284002B_ABST
Patent Text Reader

Abstract

The present invention discloses a compound with antifungal activity or a pharmaceutically acceptable salt thereof, the general structural formula of which is selected from one of the following structures: #imgabs0# The compounds of the present invention have strong inhibitory activity against both BET and HDAC, among which a part of the compounds have higher selective inhibitory activity against total HDAC of fungi, while maintaining highly efficient synergistic antifungal activity, reducing the cytotoxicity to normal human cells, having excellent in vivo anti-drug-resistant fungal infection effect, and reducing fungal toxicity from various aspects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a compound with antifungal activity and application thereof. Background Art

[0002] Invasive fungal infections (IFIs) have become a serious threat to public health due to the rapid development of fungal resistance and the limited efficacy of existing antifungal drugs. IFIs cause millions of deaths worldwide each year, and this threat of death is particularly serious for immunocompromised people. Candida species, especially Candida albicans, are the main pathogens of invasive fungal diseases, causing disseminated candidiasis. Currently, only four classes of drugs are approved for the treatment of invasive candidiasis, namely azoles, polyenes, echinocandins, and pyrimidines. Azoles (such as fluconazole, FLC) are widely used in clinical practice as the first-line treatment of candidiasis. However, since FLC is a bacteriostatic agent and has no fungicidal effect, it is likely to lead to clinical treatment failure and fungal resistance to azoles. Given the high mortality rate of invasive fungal diseases in immunocompromised patients and the limited number of available drugs, the development of new antifungal treatment strategies is urgently needed.

[0003] In recent years, significant progress has been made in the discovery of antifungal drug targets, such as heat shock protein 90 (Hsp90), KIX protein, GPI anchor protein, etc. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) jointly regulate the acetylation level in Candida albicans cells, thereby affecting cell growth, virulence, stress response and drug resistance. In Candida, the important functions of HDAC proteins have been widely studied, including the regulation of fungal virulence functions such as life cycle, morphological transformation, gray-white transformation, and biofilm formation. More importantly, HDACs have been shown to be involved in the development of azole resistance (J. Antimicrob. Chemother. 2015, 70, 1993-2003). Therefore, the inhibition of fungal HDACs is expected to reduce the virulence of fungi and improve the efficacy of existing antifungal drugs, thereby overcoming the problem of fungal resistance.

[0004] Typical HDAC inhibitors contain a cap structure (cap), a zinc binding region (ZBG) and a suitable linker. Studies have shown that HDAC exhibits synergistic anti-tumor effects with multiple anti-tumor targets such as p53, heat shock protein (Hsp90), topoisomerase (Top) and tubulin. Multi-target drug research targeting HDAC and synergistic targets has become an effective means to overcome tumor resistance and enhance anti-tumor efficacy. Currently, several HDAC multi-target inhibitors have entered clinical or preclinical studies. Some existing HDACs inhibitors, such as vorinostat (SAHA), trichostatin A (TSA), MGCD290, etc., can significantly enhance their antifungal activity when used in combination with FLC, and have no antifungal activity when used alone. This means that the combination of HDACs inhibitors and azole drugs is a very promising therapeutic strategy against drug-resistant Candida albicans. However, existing HDAC inhibitors lack selectivity for fungal HDACs and may have host toxicity issues to normal organisms.

[0005] As epigenetic readers, bromodomain and extra-terminal family proteins (BET) recognize acetylated lysine residues in the tail of histones through two bromodomains (BD1 and BD2) in their structure to regulate gene expression and participate in the occurrence and development of cancer. Considering the role of simultaneous blocking of BET and HDAC in cancer cell processes (Angew. Chem. Int. Ed. Engl. 2020, 59, 3028-3032), and the efficacy of BRD4-HDAC dual-target inhibitors in anti-tumor and anti-fungal aspects (J. Med. Chem. 2023, acs. jmedchem. 2c01191), a series of BRD4-HDAC dual-target inhibitors were developed and evaluated. These compounds showed extremely strong selective activity against fungal HDACs, as well as excellent synergistic antifungal activity in combination with FLC against drug-resistant Candida albicans. Summary of the invention

[0006] The first object of the present invention is to provide a compound having antifungal activity.

[0007] The second object of the present invention is to provide a use of the compound having antifungal activity in the preparation of a BET-HDAC dual-target inhibitor.

[0008] The third object of the present invention is to provide a use of the compound having antifungal activity in the preparation of antifungal drugs.

[0009] The fourth object of the present invention is to provide a use of the compound having antifungal activity in conjunction with fluconazole in the preparation of antifungal drugs.

[0010] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0011] The first aspect of the present invention provides a compound having antifungal activity or a pharmaceutically acceptable salt thereof, the general structural formula of which is selected from one of the following structures:

[0012]

[0013] in:

[0014] R 11 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0015] R 12 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0016] R 13 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0017] R 14 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0018] X is selected from

[0019]

[0020] R 15 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0021] R 16 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0022] R 17 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0023] R 18 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0024] R19 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0025] Y is selected from

[0026]

[0027] R 20 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0028] R 21 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0029] R 22 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0030] R 23 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy;

[0031] R 24 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine), C1-C10 alkyl, C1-C10 alkoxy.

[0032] More preferably, among the compounds having antifungal activity,

[0033] R 11 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy;

[0034] R 12 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy;

[0035] R 13 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy;

[0036] R 14 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy;

[0037] X is selected from

[0038]

[0039] R 15 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 16is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 17 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 18 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 19 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; Y is selected from

[0040]

[0041] R 20 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 21 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 22 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 23 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy; R 24 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, methoxy, ethoxy, tert-butoxy. Most preferably, the compound having antifungal activity is selected from one of the following structures:

[0042]

[0043]

[0044]

[0045] The second aspect of the present invention provides a use of the compound having antifungal activity or a pharmaceutically acceptable salt thereof in the preparation of a BET-HDAC dual-target inhibitor.

[0046] BET and HDAC are epigenetic targets. BET proteins can recognize acetylated lysine on cell histones, bind to histones through bromodomains and regulate gene transcription, while HDACs recognize acetylated lysine on histones and deacetylate histones, thereby regulating gene expression. By reducing the expression of related efflux pump proteins, drug efflux can be reduced, the drug resistance of fungal cells can be reversed, and combined with antifungal drugs, it can play a role in resisting drug-resistant fungi.

[0047] The third aspect of the present invention provides a use of the compound having antifungal activity or a pharmaceutically acceptable salt thereof in the preparation of an antifungal drug.

[0048] The fungus is selected from Cryptococcus neoformans, drug-resistant Candida albicans, and Candida albicans.

[0049] The fourth aspect of the present invention provides a use of the compound having antifungal activity or a pharmaceutically acceptable salt thereof in combination with fluconazole in the preparation of an antifungal drug.

[0050] The compounds with antifungal activity described in the present invention have excellent synergistic FLC effects against drug-resistant Candida albicans in in vitro and in vivo antifungal activity tests, and have inhibitory effects on virulence factors of Candida albicans, effectively inhibiting the production of fungal biofilms (Example 32) and morphological transformation (Example 33).

[0051] The fungus is selected from Cryptococcus neoformans, drug-resistant Candida albicans, and Candida albicans.

[0052] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0053] The enzyme inhibition activity and in vitro antifungal activity tests of the compounds of the present invention found that the compounds of the present invention had an inhibition rate of 91.8% on BET (the one with the best activity at a concentration of 1 μM, Example 29) and HDAC1 (the one with the best activity at IC 50 0.062 μM, Example 29) all have good inhibitory activity, and most compounds show selective inhibitory activity against total fungal HDACs (the best selectivity can reach 3023 times, Example 29). This fungal selectivity greatly reduces the cytotoxicity of this type of compound (Example 30). Most compounds have strong in vitro antifungal activity, and the antifungal activity against drug-resistant Candida albicans 0304103 when used in combination with FLC and the antifungal activity against Cryptococcus neoformans H99 when used alone show better inhibitory activity than single-target drugs (+)-JQ1 and SAHA (Example 30).

[0054] In the in vivo antifungal test of the compounds of the present invention, it was found that the preferred compound B2, when used in combination with FLC, can significantly reduce the bacterial load in the kidney tissue of mice in the candidiasis mouse model (Example 31), and there are significant differences compared with the blank group and the single-dose group (P<0.05), showing the characteristics of high efficiency and low toxicity, and is an excellent antifungal drug.

[0055] The invention opens up a new path and provides a new strategy for in-depth research and development of antifungal drugs of new structural types.

[0056] The compounds of the present invention have strong inhibitory activity against both BET and HDAC, and some of the compounds have higher selective inhibitory activity against total HDAC of fungi. While maintaining highly efficient synergistic antifungal activity, they reduce the cytotoxicity to normal human cells, have excellent in vivo anti-drug-resistant fungal infection effects, and reduce fungal toxicity from various aspects. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 Schematic diagram of the in vivo therapeutic effects of compound B2 and FLC in the candidiasis mouse model.

[0058] Figure 2 Schematic diagram of the growth curve of resistant Candida albicans 0304103 over time under the combined action of different concentrations of compound B2 and FLC.

[0059] Figure 3 Schematic diagram of biofilm formation of drug-resistant Candida albicans 0304103 under the combined action of different concentrations of compound B2 and FLC.

[0060] Figure 4 Schematic diagram of the effects of compound B2 and FLC alone or in combination on the hyphae formation of drug-resistant Candida albicans 0304103.

[0061] Figure 5 Schematic diagram of the effects of compound B2 and FLC on different drug-resistant genes when used alone or in combination. DETAILED DESCRIPTION

[0062] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0063]

[0064] Scheme 1.Reagents and conditions: (a) Fmoc-Asp(OtBu)-OH, EDCI, HOBT, DCM, 40℃; (b) i.pyridine, DMF, rt; ii. EtOH, AcOH, 80℃; (c)it-BuOK,CIP(O)(OPh)2,THF,-78℃; ii.CH3CON2H3,THF / n-BuOH,90℃; (d)TFA,rt; (e)Various aromatic amino-esters(12),HATU,TEA,DMF,rt; (f)NH2OH-HCl,CH3OH,rt.

[0065]

[0066] Scheme 2.Reagents and conditions: (a) Fmoc-Asp(OtBu)-OH, EDCI, HOBT, DCM, 40℃; (b) i.pyridine, DMF, rt; ii. EtOH, AcOH, 80℃; (c)it-BuOK,CIP(O)(OPh)2,THF,-78℃; ii.CH3CON2H3,THF / n-BuOH,90℃; (d)TFA,rt; (e)Various aromatic amino-esters(12),HATU,TEA,DMF,rt; (f)NH2OH-HCl,CH3OH,rt.

[0067]

[0068]

[0069] Scheme 3.Reagents and conditions: (a) Fmoc-Asp(OtBu)-OH, EDCI, HOBT, DCM, 40℃; (b) i.pyridine, DMF, rt; ii. EtOH, AcOH, 80℃; (c)it-BuOK,CIP(O)(OPh)2,THF,-78℃; ii.CH3CON2H3,THF / n-BuOH,90℃; (d)TFA,rt; (e)Various aromatic amino-esters(12),HATU,TEA,DMF,rt; (f)NH2OH·HCl,CH3OH,rt.

[0070] Example 1

[0071] (S)-4-(2-(1-methyl-6-phenyl-4H-[1,2,4]-triazolo[4,3-a]benzo[f][1,4]diazolyl Preparation of 4-(4-yl)acetylamino)-N-hydroxybenzamide (A1)

[0072] (1) Preparation of Intermediate 8a: (S)-tert-butyl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((2-benzoylphenyl)amino)-4-oxobutanoate

[0073] Fmoc-Asp-OtBu (10.00 g, 24.33 mmol) was dissolved in DCM (40 mL), and EDC-HCl (5.05 g, 26.34 mmol), HOBT (2.47 g, 18.25 mmol) and starting material 7a (4.00 g, 20.28 mmol) were added in sequence. The reaction mixture was refluxed at 40 °C for 24 h. 40 mL of water was added to the reaction solution, and the organic phases were combined after extraction with DCM (2 × 40 mL). The organic phases were washed with saturated NH4Cl (2 × 20 mL) and saturated aqueous NaCl solution (2 × 20 mL), dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (Hexane / EtOAc = 10 / 1–5 / 1). 6.80 g of yellow-white solid product was obtained, with a yield of 56.8%. 1 H NMR (600MHz, CDCl3) δ11.72(s,1H),8.65(d,J=8.3Hz,1H),7.76(d,J=7.4Hz,2H),7.71(d,J=7.2 Hz,1H),7.64(d,J=7.2Hz,1H),7.60–7.54(m,4H),7.51(t,J=7.4Hz,1H),7.40–7.34(m,4H),7.2 5–7.20(m,2H),7.10(t,J=7.5Hz,1H),6.16(d,J=9.1Hz,1H),4.79–4.74(m,1H),4.68–4.61(m,1 H),4.38–4.23(m,2H),3.15(dd,J=17.0,4.6Hz,1H),2.76(dd,J=17.0,4.3Hz,1H),1.43(s,9H). 13 C NMR(151MHz,DMSO-d6)δ196.87(s),170.22(s),169.64(s),156.43(s),144.33(s),144.15(s),141. 18(s),141.16(s),137.87(s),137.83(s),133.26(s),133.13(s),131.90(s),130.09(s,2C),128.7 7(s,2C),128.07(s,2C),127.98(s),127.47(s,2C),125.77(s),125.69(s),124.11(s),122.76(s), 120.52(s,2C),80.71(s),66.44(s),52.73(s),47.07(s),37.11(s),28.15(s,3C).ESI-HRMS:calcd for C36 H 34 N2O6:m / z:[M+Na] + =613.2309; found [M + Na] + =613.2312.

[0074] (2) Preparation of Intermediate 9a

[0075] Compound 8a (6.80 g, 11.50 mmol) was dissolved in DMF (20 mL), and piperidine (11 mL) was added thereto. The reaction solution was stirred at room temperature for 1 h, poured into water (30 mL), and extracted with EtOAc (3×40 mL). The combined organic phase was washed with saturated aqueous NaCl solution (2×20 mL), dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude product after removal of Fmoc protection. The crude product was directly used for the next cyclization reaction without purification.

[0076] The above product was dissolved in EtOH (130 mL), AcOH (30 mL) was added thereto, and the mixture was stirred at 80°C for 2 h. After concentration under reduced pressure, it was redissolved in EtOAc (100 mL) and washed with saturated NaHCO3 (2×30 mL). The organic phase was collected, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (hexane / EtOAc=5 / 1). 3.39 g of white solid powder was obtained, with a yield of 84.2%. 1 H NMR(600MHz, CDCl3)δ9.76(s,1H),7.55–7.51(m,3H),7.47–7.43(m,1H),7.41–7.36(m,2H),7.36–7.34(m,1H),7.23(d,J= 8.2Hz,1H),7.19–7.15(m,1H),4.17–4.14(m,1H),3.38(dd,J=16.9,7.3Hz,1H),3.18(dd,J=16.8,6.7Hz,1H),1.51(s,9H). 13 C NMR(151MHz,DMSO)δ170.85(s),170.41(s),168.62(s),139.59(s),139.12(s),132.21(s),130.86(s),130.76(s),129.76 (s,2C),128.70(s,2C),126.97(s),123.34(s),121.67(s),80.26(s),60.94(s),37.73(s),28.23(s,3C).ESI-HRMS:calcd forC 21 H22 N2O3:m / z:[M+H] + =351.1703; found [M+H] + =351.1702.

[0077] (3) Preparation of Intermediate 10a

[0078] Compound 9a (5.07 g, 14.49 mmol) was dissolved in THF (24 mL). After the solution was cooled to -78 ° C, potassium tert-butoxide (1.79 g, 15.94 mmol) was slowly added thereto. After potassium tert-butoxide was added, the reaction mixture was heated to -10 ° C and continued to stir and react at this temperature for 30 min. The reaction was cooled to -78 ° C, ClP (O) (OPh) 2 (4.56 g, 17.03 mmol) was added thereto, the temperature was raised to -10 ° C, and the reaction was stirred at this temperature for 45 min. Then acetylhydrazine (1.93 g, 26.08 mmol) was added to the reaction solution, and tert-butanol (18 mL) was added after stirring at room temperature for 1 h. The reaction was stirred at 90 ° C for 1 h. After cooling to room temperature, DCM (80 mL) was added after concentrating under reduced pressure, and the organic phase was washed with saturated NaHCO 3 (2 × 20 mL) and saturated NaCl aqueous solution (2 × 20 mL), respectively. The organic phase was collected, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM / MeOH=100 / 3) to obtain 2.83 g of a white solid product with a yield of 50.3%. 1 H NMR (600MHz, CDCl3) δ7.71–7.67(m,1H),7.51(dd,J=8.3,1.3Hz,2H),7.49–7.47(m,3H),7.46–7.42(m,1H),7.38–7.34(m ,2H),4.57(dd,J=8.2,5.9Hz,1H),3.57(dd,J=16.8,8.2Hz,1H),3.53(dd,J=16.8,5.9Hz,1H),2.67(s,3H),1.50(s,9H). 13C NMR(151MHz,DMSO-d6)δ170.39(s),167.60(s),156.26(s),151.22(s),139.09(s),133.63(s),132.44(s),131.47(s),131.02(s),129. 70(s,2C),128.92(s),128.65(s,2C),127.91(s),124.50(s),80.63(s),53.40(s),37.92(s),28.26(s),12.06(s,3C).ESI-HRMS:calcd for C 23 H 24 N4O2:m / z:[M+H] + =389.1972; found [M+H] + =389.1978.

[0079] (4) Preparation of Intermediate 11a

[0080] Compound 10a (2.70 g, 6.96 mmol) was dissolved in TFA (10 mL) and stirred at room temperature overnight. The mixture was concentrated under reduced pressure, and toluene was added to the residue and the mixture was further concentrated under reduced pressure to remove the remaining TFA. Ether was added to the concentrate to precipitate a solid product. The solid product was filtered and washed with EtOAc to obtain 1.93 g of a white solid product, with a yield of 83.5%. 1 H NMR(600MHz,DMSO-d6)δ7.88(dd,J=8.2,0.9Hz,1H),7.85–7.81(m,1H),7.60(td,J=7.8,1.2Hz,1H),7.52–7.47(m,3H), 7.45–7.40(m,3H),4.43(dd,J=7.6,6.7Hz,1H),3.41(dd,J=16.7,6.6Hz,1H),3.34(dd,J=16.7,7.7Hz,1H),2.61(s,3H). 13 C NMR(151MHz,DMSO-d6)δ172.52(s),167.69(s),156.35(s),151.48(s),139.04(s),133.39(s),132.48(s),131.61(s),131 .05(s),129.80(s,2C),128.96(s),128.64(s,2C),128.10(s),124.56(s),53.25(s),37.00(s),12.03(s).ESI-HRMS:calcd for C 19 H 16N4O2:m / z:[M+H] + =333.1346; found [M+H] + =333.1355.

[0081] (5) Preparation of intermediate a1

[0082] Compound 11a (0.28 g, 0.85 mmol) was dissolved in DMF (5 mL), and Et3N (235 μL, 1.70 mmol), HATU (0.34 g, 0.88 mmol) and methyl para-aminobenzoate (12, 0.13 g, 0.88 mmol) were added to the reaction solution in sequence. The reaction solution was stirred at room temperature overnight. Saturated aqueous NaCl solution was added to the reaction mixture, extracted with EtOAc (3×20 mL), and the organic phases were combined and washed with 1N HCl, saturated NaHCO3, and saturated aqueous NaCl solution, respectively. The organic phase was dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM / MeOH=100 / 2–100 / 4) to obtain 0.25 g of a white solid product with a yield of 63.5%. 1 H NMR (600MHz, DMSO-d6) δ10.70(s,1H),7.93(d,J=8.8Hz,2H),7.88(d,J=7.3Hz,1H ),7.85–7.81(m,1H),7.78(d,J=8.8Hz,2H),7.61–7.56(m,1H),7.49–7.45(m,3H) ,7.43(dd,J=7.8,1.2Hz,1H),7.41–7.37(m,2H),4.57(dd,J=8.0,6.3Hz,1H),3.8 3(s,3H),3.58(dd,J=15.5,8.1Hz,1H),3.51(dd,J=15.5,6.3Hz,1H),2.59(s,3H). 13 CNMR(151MHz,DMSO-d6)δ169.92(s),167.77(s),166.29(s),156.53(s),151.30( s),144.01(s),139.12(s),133.65(s),132.45(s),131.58(s),131.01(s),130.7 9(s,2C),129.75(s,2C),128.95(s),128.63(s,2C),127.92(s),124.52(s),124. 36(s),118.92(s,2C),53.48(s),52.33(s),39.31(s),12.08(s).ESI-HRMS:calcd for C27 H 23 N5O3:m / z:[M+H] + =466.1874; found[M+H] + =466.1862.

[0083] (6) Preparation of target product A1

[0084] Hydroxylamine hydrochloride (4.67 g, 0.67 mol) was dissolved in 24 mL of anhydrous methanol, and KOH (5.61 g, 50 mmol) and 2.00 g of anhydrous magnesium sulfate were added thereto under ice bath conditions. The mixture was stirred at this temperature for 30 min and then filtered to obtain a freshly prepared hydroxylamine solution.

[0085] Compound a1 (0.11 g, 0.24 mmol) was added to a 25 mL eggplant-shaped bottle, and 7 mL of freshly prepared hydroxylamine solution was added thereto. The mixture was stirred and reacted at 0°C for 10 h. The solvent was removed by concentration under reduced pressure, 10 mL of water was added to the concentrate, 2N HCl was added dropwise to the suspension, and the pH value was adjusted to 6-7. The obtained suspension was filtered, and the obtained solid was washed with H2O and dried to obtain a crude product. The crude product was separated and purified by HPLC (MeOH / H2O=55 / 45–70 / 30) to obtain 63 mg of a white solid product with a yield of 56.3%. 1 H NMR (600MHz, DMSO-d6) δ11.11(s,1H),10.56(s,1H),8.95(s,1H),7.88(dd,J=8.1,0.9Hz ,1H),7.85–7.81(m,1H),7.73(d,J=8.9Hz,2H),7.70(d,J=9.0Hz,2H),7.59(td,J=7.8,1. 2Hz,1H),7.50–7.45(m,3H),7.43(dd,J=7.8,1.3Hz,1H),7.41–7.38(m,2H),4.57(dd,J= 8.2, 6.2Hz, 1H), 3.57 (dd, J=15.5, 8.2Hz, 1H), 3.49 (dd, J=15.4, 6.1Hz, 1H), 2.59 (s, 3H). 13CNMR(151MHz,DMSO-d6)δ169.72(s),167.82(s),164.55(s),156.57(s),151.3 8(s),142.13(s),139.07(s),133.53(s),132.51(s),131.55(s),131.05(s),1 29.70(s,2C),128.94(s),128.65(s,2C),128.21(s,2C),128.00(s),127.63(s ),124.48(s),118.92(s,2C),67.65(s),53.47(s),12.00(s).ESI-HRMS:calcd for C 26 H 22 N6O3:m / z:[M+H] + =467.1826,[MH] - =465.1680; found[M+H] + =467.1844,[MH] - =465.1694.

[0086] Example 2

[0087] The methyl p-aminobenzoate in step (5) of Example 1 was replaced by methyl 4-(aminomethyl)benzoate, and the rest was the same as in Example 1 to obtain compound A2.

[0088] Example 3

[0089] The methyl p-aminobenzoate in step (5) of Example 1 was replaced by methyl 2-(4-aminophenyl)acetate, and the rest was the same as in Example 1 to obtain compound A3.

[0090] Example 4

[0091] The methyl p-aminobenzoate in step (5) of Example 1 was replaced by (E)-3-(4-aminophenyl)-2-methyl propenoate, and the rest was the same as in Example 1 to obtain Compound A4.

[0092] Example 5

[0093] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-methylbenzophenone (7b), and the rest was the same as in Example 1 to obtain compound A5.

[0094] Example 6

[0095] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-methylbenzophenone (7b), and the methyl p-aminobenzoate in step (5) was replaced by methyl 4-(aminomethyl)benzoate, and the rest was the same as in Example 1 to obtain Compound A6.

[0096] Example 7

[0097] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-methylbenzophenone (7b), and the methyl p-aminobenzoate in step (5) was replaced by methyl 2-(4-aminophenyl)acetate, and the rest was the same as in Example 1 to obtain compound A7.

[0098] Example 8

[0099] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-methylbenzophenone (7b), and the methyl p-aminobenzoate in step (5) was replaced by (E)-3-(4-aminophenyl)-2-propenoic acid methyl ester, and the rest was the same as in Example 1 to obtain Compound A8.

[0100] Example 9

[0101] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-chlorobenzophenone (7c), and the rest was the same as in Example 1 to obtain compound A9.

[0102] Example 10

[0103] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-chlorobenzophenone (7c), and the methyl p-aminobenzoate in step (5) was replaced by methyl 4-(aminomethyl)benzoate, and the rest was the same as in Example 1 to obtain Compound A10.

[0104] Embodiment 11

[0105] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-chlorobenzophenone (7c), and the methyl p-aminobenzoate in step (5) was replaced by methyl 2-(4-aminophenyl)acetate, and the rest was the same as in Example 1 to obtain Compound A11.

[0106] Example 12

[0107] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-4'-chlorobenzophenone (7c), and the methyl p-aminobenzoate in step (5) was replaced by (E)-3-(4-aminophenyl)-2-propenoic acid methyl ester, and the rest was the same as in Example 1 to obtain Compound A12.

[0108] Embodiment 13

[0109] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-2',5-dichlorobenzophenone (7d), and the rest was the same as in Example 1 to obtain compound A13.

[0110] Embodiment 14

[0111] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-2',5-dichlorobenzophenone (7d), and the methyl p-aminobenzoate in step (5) was replaced by methyl 4-(aminomethyl)benzoate, and the rest was the same as in Example 1 to obtain Compound A10.

[0112] Embodiment 15

[0113] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-2',5-dichlorobenzophenone (7d), and the methyl p-aminobenzoate in step (5) was replaced by methyl 2-(4-aminophenyl)acetate, and the rest was the same as in Example 1 to obtain Compound A15.

[0114] Example 16

[0115] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-2',5-dichlorobenzophenone (7d), and the methyl p-aminobenzoate in step (5) was replaced by (E)-3-(4-aminophenyl)-2-methyl propenoate, and the rest was the same as in Example 1 to obtain Compound A16.

[0116] Embodiment 17

[0117] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chloro-2'-fluorobenzophenone (7e), and the rest was the same as in Example 1 to obtain compound A17.

[0118] Embodiment 18

[0119] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chloro-2'-fluorobenzophenone (7e), and the methyl p-aminobenzoate in step (5) was replaced by methyl 4-(aminomethyl)benzoate, and the rest was the same as in Example 1 to obtain Compound A18.

[0120] Embodiment 19

[0121] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chloro-2'-fluorobenzophenone (7e), and the methyl p-aminobenzoate in step (5) was replaced by methyl 2-(4-aminophenyl)acetate. The other steps were the same as in Example 1 to obtain Compound A19.

[0122] Embodiment 20

[0123] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chloro-2'-fluorobenzophenone (7e), and the methyl p-aminobenzoate in step (5) was replaced by (E)-3-(4-aminophenyl)-2-propenoic acid methyl ester, and the rest was the same as in Example 1 to obtain compound A20.

[0124] Embodiment 21

[0125] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chlorobenzophenone (7f), and the rest was the same as in Example 1 to obtain compound A21.

[0126] Embodiment 22

[0127] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chlorobenzophenone (7f), and the methyl p-aminobenzoate in step (5) was replaced by methyl 4-(aminomethyl)benzoate, and the rest was the same as in Example 1 to obtain compound A22.

[0128] Embodiment 23

[0129] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chlorobenzophenone (7f), and the methyl p-aminobenzoate in step (5) was replaced by methyl 2-(4-aminophenyl)acetate, and the rest was the same as in Example 1 to obtain compound A23.

[0130] Embodiment 24

[0131] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by 2-amino-5-chlorobenzophenone (7f), and the methyl p-aminobenzoate in step (5) was replaced by (E)-3-(4-aminophenyl)-2-propenoic acid methyl ester, and the rest was the same as in Example 1 to obtain compound A24.

[0132] Embodiment 25

[0133] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone (7g), and the rest was the same as in Example 1 to obtain Compound B1.

[0134] Embodiment 26

[0135] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone (7g), and the methyl p-aminobenzoate in step (5) was replaced by methyl 4-(aminomethyl)benzoate, and the rest was the same as in Example 1 to obtain compound B2.

[0136] Embodiment 27

[0137] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone (7g), and the methyl p-aminobenzoate in step (5) was replaced by methyl 2-(4-aminophenyl)acetate, and the rest was the same as in Example 1 to obtain compound B3.

[0138] Embodiment 28

[0139] The 2-aminobenzophenone (7a) in step (1) of Example 1 was replaced by (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone (7g), and the methyl p-aminobenzoate in step (5) was replaced by (E)-3-(4-aminophenyl)-2-methyl propenoate, and the rest was the same as in Example 1 to obtain compound B4.

[0140] Table 1. Structural formula and NMR mass spectrometry data of the compounds of the present invention

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149] Embodiment 29

[0150] Enzyme Inhibitory Activity of Compounds Prepared in Examples 1 to 28

[0151] 1. BET activity study and test of target compounds

[0152] The experiment was conducted using the time-resolved fluorescence analysis (TR-FRET) test method:

[0153] (1) Prepare 1×TR-FRET Assay Buffer (Item No. 600503). Dilute the test compound (100 μM) with the buffer to obtain a test sample with a concentration of 2 μM, and make the final DMSO concentration in each test well 1%. Make triplicate wells and repeat twice.

[0154] (2) Add 10 μL of BRD protein diluted with 1× Buffer, 5 μL of BRD protein ligand, and 5 μL of the test compound to each test well of the 96-well plate and mix thoroughly. Set up a negative control and a positive control group for each test plate. No compound sample is added to the negative control, and (+)-JQ1 is used in the positive control.

[0155] (3) The 96-well plate was incubated at 20°C in the dark with shaking for 60 minutes, and then the excitation light was 340 nm and the emission light was read at 670 nm.

[0156] (4) According to the measured readings, fitting was performed in GraphPad 5.0 software to obtain the IC of the compound. 50 value.

[0157] 2. Target compound HDAC1 enzyme inhibition test

[0158] 2.1 Experimental materials: HDAC1 enzyme, buffer (137 mM sodium chloride, 2.7 mM potassium chloride, 1 mM magnesium chloride, 0.1 mg / mL BSA, Tris-HCl 25 mM, pH = 8), HDAC substrate 3, trypsin, 96-well black plate.

[0159] 2.2 Experimental methods:

[0160] (1) The 96-well black plate is equilibrated to room temperature;

[0161] (2) diluting the test compound with a buffer solution containing 10% DMSO, the concentrations of the compound were 100 μM, 30 μM, 10 μM, 3 μM, 1 μM, 0.3 μM, 0.1 μM, 0.03 μM, 0.01 μM, 0.003 μM;

[0162] (3) Add 11 μL of HDAC1 to 400 μL of buffer and shake well;

[0163] (4) Add 35 μL of the prepared buffer containing HDAC1 enzyme to wells 2-11 of the 96-well plate, and add 5 μL of the diluted compounds of different concentrations to the corresponding reaction wells in sequence. For the negative control (the first well) and the blank control well (the eleventh well), add 40 μL and 5 μL of assay buffer, respectively;

[0164] (5) Add 5 μL of 100 μM HDAC substrate and 5 μL of 0.5 mg / mL trypsin to all reaction wells, incubate at 37°C for 30 min, and read the results.

[0165] (6) Calculate the inhibition rate according to the formula: Inhibition rate = (100% active wells - sample wells) / 100% active wells × 100. Fit the curve of enzyme activity to compound concentration in GraphPad software to calculate the IC value of the compound. 50 value;

[0166] 3. Inhibition test of target compound fungal total HDACs and human total HDAC enzymes

[0167] 3.1 Experimental Materials

[0168] Pretreatment solution (10mmol / L Tris-10mmol / L EDTA, 0.4% mercaptoethanol), protoplast stabilization solution (0.6mol / LNaCl, 50mmol / L glycine, 1mmol / L CaCl2, pH=6.0), HDAC buffer (137mM sodium chloride, 2.7mM potassium chloride, 1mM magnesium chloride, 0.1mg / mL BSA, Tris-HCl 25mM, pH=8), substrate Boc-Lys(Ac)-AMC, stop solution (0.5mg / mL trypsin and 1% NP40 dissolved in HDAC buffer), YPD medium, black 96-well plate.

[0169] 3.2 Cell lines

[0170] Resistant Candida albicans cells (0304103), human umbilical vein epithelial cells (HUVEC).

[0171] 3.2 Experimental methods

[0172] Exponentially growing Candida albicans cells (0304103) were dispersed in 40 mL of YPD medium to a concentration of 10 6cells / mL. After the fungal suspension was shaken and cultured at 35°C for 24 hours, the fungal cells were collected by centrifugation and washed with PBS (2×5mL). The fungal cells were resuspended in the pretreatment solution and incubated at 30°C with shaking for 60 minutes. The cells were collected by centrifugation, washed with protoplast stabilization solution, and resuspended in 10mL of protoplast stabilization solution containing 1.0% snailase, and incubated at 37°C with shaking for 90 minutes to obtain protoplasts. The centrifuged protoplasts were resuspended in 5mL of protoplast stabilization solution, and the protoplasts were counted using a cell counting plate. The fungal protoplasts were diluted with protoplast stabilization solution to a concentration of 1×10 8 cells / mL suspension was added to a black 96-well plate (BG row, 2-11 columns, 100μL per well; BG row, 1 column, 150μL per well). The compound to be tested was then added to the fungal suspension in column 1 to a concentration of 10μM, and then three-fold diluted to column 10 to a concentration range of 0.5-10000nM. 100μL of blank protoplast stabilization solution was added to the remaining wells. After the sample was incubated at 35°C for 12h, the HDAC substrate Boc-Lys(Ac)-AMC was dissolved in HDAC buffer to a concentration of 100μM, and the substrate solution was added to the 96-well plate, 30μL per well, and incubated at 37°C for 6h. 20μL / well of stop solution was added to the culture dish and reacted at 37°C for 2h. Finally, the fluorescence intensity was analyzed on a Spectra MaxM5 microplate reader with an excitation wavelength of 360 nm and an emission wavelength of 460 nm. The inhibition rate was calculated using the same formula as in Experiment 2 in Example 29. IC was calculated using nonlinear regression using Prism GraphPad software. 50 Value. HUVEC cells were used for human total HDACs inhibition assay, which was similar to the fungal total HDACs inhibition assay with only slight differences. No protoplast preparation was required, and the initial number of HUVEC cells, 15,000 cells / well, was incubated at 37°C and 5% CO2 for 24 hours to complete adhesion and proliferation. Other steps were performed according to the fungal total HDACs inhibition assay.

[0173] The experimental results are shown in Table 1. Most compounds showed good HDAC1 inhibitory activity, IC 50 Range: 0.062~2.7μM. Structure-activity relationship studies have shown that the introduction of methylene groups into the aromatic side chains will lead to a decrease in the inhibitory activity against HDAC1 (A1>A2>A3, A5>A6>A7, A9>A10>A11, A13>A15>A14, B1>B3>B2), while the side chain groups in the form of cinnamic acid basically maintain the inhibitory activity of the compound against HDAC1 (A4 IC 50 =0.63μM, A8IC 50 =0.18μM, A12 IC 50=0.1μM, B4 IC 50 =0.79μM, A24 IC 50 =0.54 μM). On the other hand, the introduction of the 3-Cl substituent and the change of the position of the 7-substituent led to a significant decrease in the inhibitory activity of the compounds against BRD4 (Scheme 2, A13-A24). In the tests of total human HDACs and total fungal HDACs, most compounds showed excellent inhibitory activity against fungal HDACs, with IC 50 Range: 0.005~9.2μM. Structure-activity relationship studies have shown that the introduction of methylene in the aromatic side chain will lead to a decrease in the inhibitory activity against fungal and human total HDACs, which is consistent with the activity test results of HDAC1 (fungal HDACs inhibitory activity: A1>A2>A3, A5>A6>A7, A9>A10>A11, A13>A14>A15, A17>A18>A19, A21>A22>A23, B1>B2>B3; human total HDACs inhibitory activity: A1>A2>A3, A5>A7>A6, A9>A10>A11, A13>A14>A15, A17>A18>A19, A21>A22>A23, B1>B3>B2). The IC values ​​of the compounds against human total HDACs were compared. 50 IC of total HDACs against fungi 50 The ratio of is defined as the selectivity index (SI). The selectivity indexes of the compounds in the table are: A2>A1>A3, A6>A5>A7, A10>A9>A11, A13>A14>A15, A17>A18>A19, A21>A22>A23, B2>B1>B3; among them, compound B2 has the strongest selectivity for fungal HDACs. In addition, compounds containing cinnamic acid side chains maintain the inhibitory activity against fungal and human total HDACs, but the selective activity of such compounds against fungal HDACs is basically lost.

[0174] Table 1. Inhibitory activity of target compounds against HDAC1 and BRD4 as well as fungal and human total HDACs

[0175]

[0176]

[0177] Embodiment 30

[0178] In vitro antifungal activity test and cytotoxicity test

[0179] 1. In vitro antifungal activity test of the compounds prepared in Examples 1 to 28

[0180] 1.1 Sample preparation

[0181] The compound to be tested was dissolved in DMSO (Merck) to a concentration of 2 mg / mL.

[0182] 1.2 Cell lines

[0183] H99 (Cryptococcus neoformans), 0304103 (resistant Candida albicans), and SC5314 (Candida albicans) were all frozen and passaged by our laboratory. Human umbilical vein epithelial cells (HUVEC).

[0184] 1.3 Culture medium

[0185] PRMI1640

[0186] 1.4 Test methods

[0187] 1.4.1 Antifungal activity MIC of the compound when used alone 80 Determination: The determination was carried out using the micro-liquid dilution method.

[0188] (1) Activation of the test strain: Take out the frozen test strain from the -80℃ refrigerator, and pipette 10μL into 1mL YEPD culture medium. Place in a 30℃ incubator and shake culture at 200rpm. After 24h, pipette 10μL from the YEPD bacterial suspension and add it to a new 1mL YEPD culture medium. Shake culture at 30℃ for 16h, and activation is complete. At this time, the fungus is in the late exponential growth stage.

[0189] (2) Preparation of bacterial suspension: Place the activated strain to be tested in a 1.5 mL centrifuge tube, centrifuge (3000 r, 1 min), discard the supernatant, wash the strain with 1 mL PBS buffer, centrifuge, discard the supernatant, and repeat 3 times. Count the strains using a hemocytometer and adjust the bacterial concentration to 1×10 using RPMI 1640 culture medium. 3 cells / mL.

[0190] (3) Add the prepared bacterial suspension to a 96-well plate (columns 1-11, rows BG), 200 μL in the first column and 100 μL in columns 2-11. Pipette 6.4 μL of the prepared drug solution into the first column and make three replicate wells to make the drug concentration 64 μg / mL. Dilute the plates from the first to the tenth columns in turn by half, that is, the concentration gradient is 0.12-64 μg / mL. No drug is added to the 11th column as a negative control group. Add blank 1640 culture medium to the outermost periphery as a blank control. Incubate in a 30°C constant temperature incubator for 48 hours and use an enzyme reader to measure the OD 630 The optical density (OD) value of the negative control group was set as 100%, and the lowest drug concentration that decreased the optical density by more than 80% compared with the negative control group was taken as the minimum inhibitory concentration (MIC). 80).

[0191] 1.4.2 Determination of synergistic antifungal activity FICI: The chessboard method was used for determination, and the optical density (OD) of the culture was used to evaluate the growth of fungi. Take 6 5mL EP tubes, add the prepared bacterial suspension into them according to the above method, 1.2mL per tube, and add the drug solution to be tested into them, so that the drug concentrations are (64, 32, 16, 8, 4, 2μg / mL) respectively. Add the drug-containing bacterial suspension in the EP tube to a 96-well plate (rows AF, columns 1-10), each drug concentration is a row, and add to rows AF from high to low drug concentrations, 200μL in the first column, and 100μL in the rest. Add blank bacterial suspension to the 11th column and wells AF as a negative control; add blank bacterial suspension to row G and wells 1-11, and the amount added is the same as above. Add FLC solution to the first column and AG wells to make the FLC concentration in each well 64μg / mL, and dilute it half-fold from the first column to the ninth column, that is, the concentration gradient is 64-0.25μg / mL. Add blank RPMI 1640 culture medium to the outermost periphery as a blank control. Incubate in a 30℃ constant temperature incubator for 48h, and use a microplate reader to measure the OD 630 Calculate the fungal inhibition rate in each drug-dosing well in the 96-well plate, and calculate the ratio of the MIC of the two combined compounds when used together to the MIC when used alone, and take the sum of the ratios as the FICI value, that is, FICI = MIC 80 (A, combined) / MIC 80 (A, alone) + MIC 80 (B, combined) / MIC 80 (B, alone). FICI < 0.5 was defined as synergistic activity.

[0192] 2. Determination of Cytotoxicity

[0193] 2.1 Sample preparation

[0194] The test compound was dissolved in DMSO (Merck) to a concentration of 10 mM.

[0195] 2.2 Cell lines

[0196] Human umbilical vein epithelial cells (HUVEC)

[0197] 2.3 Culture medium

[0198] DMEM

[0199] 2.4 Test methods

[0200] Human umbilical vein endothelial cells (HUVEC) were used in this experiment. The cells were suspended in DMEM and seeded into a 96-well transparent plate, 9000 cells / well. Incubate at 37°C and 5% CO2 for 24 hours. The compound was then added to the 96-well transparent plate to a final drug concentration of 0.015-100 μM, and three-fold dilutions were made. After incubation at 37°C and 5% CO2 for 48 hours, 10 μL of CCK8 was added to each well and incubated at 37°C for 30-50 minutes. The optical density at 450nm (OD450) was measured using an enzyme reader. The cell growth inhibition rate of the compound at each concentration was calculated, and the IC was calculated using GraphPad Prism nonlinear analysis. 50 .

[0201] The experimental results are shown in Table 2. When used alone, the compound has no inhibitory activity against Candida albicans SC5314, and has a certain antifungal effect on Cryptococcus neoformans H99. This series of compounds has a significant synergistic antifungal effect (FICI <0.5) when used in combination with FLC. Among them, the synergistic antifungal activity of compound B2 is the best (FICI = 0.063), which is better than the positive control drugs SAHA and (+)-JQ1. In the cytotoxicity test, the compound showed significant low cytotoxicity. In view of the significant synergistic antifungal activity and low cytotoxicity of compound B2, compound B2 is preferred for further in vivo antifungal treatment effect and cytotoxicity investigation.

[0202] Table 2. In vitro antifungal activity (MIC 80 , μg / mL) and cytotoxicity (IC 50 , μM)

[0203]

[0204]

[0205] Embodiment 31

[0206] In vivo antifungal activity of preferred compound B2

[0207] Based on the results of in vitro antifungal experiments, cytotoxicity, and selectivity for total fungal HDACs, compound B2 was selected as the structural characteristics of the research object compound, and the in vivo therapeutic effect of compound B2 against invasive candidiasis caused by drug-resistant Candida albicans 0304103 was continued. The animal laboratory complies with IACUC standards (license number SYXK-2017-0004). ICR mice were randomly divided into four groups, with 5 mice in each group. Then, a concentration of 1×10 6The mice were infected by tail vein injection of 0.2 mL of drug-resistant Candida albicans cells 0304103 cells / mL. Two hours after infection, the drug was dissolved in physiological saline (containing 1.5% glycerol and 0.5% Tween 80), and compound B2 (10 mg / kg) and FLC (1 mg / kg) were administered alone or in combination by intraperitoneal injection. The blank group was given blank solvent. After continuous administration for 5 days, the kidneys were removed and ground evenly. The tissue homogenate was diluted 1000 times and spread on SDA medium containing chloramphenicol. It was incubated at 30°C for 48 hours, the colonies on the culture medium were counted, and the fungal concentration in the tissue homogenate and the bacterial load of the mouse kidney per unit mass were calculated. The logarithmic value of the bacterial load of the mouse kidney was plotted using GraphPad Prism, and the differences between the groups were analyzed using ANOVA.

[0208] The experimental results are as follows Figure 1 As shown, Figure 1 Schematic diagram of the in vivo therapeutic effect of compound B2 and FLC in a mouse model of candidiasis. The ordinate is the logarithm of the fungal load in the kidney tissue per unit weight of the mouse. As can be seen from the figure, compound B2 alone has no therapeutic effect, while FLC has a weak therapeutic effect (P<0.05). However, when the two are used in combination, the bacterial load in the mouse kidneys is significantly reduced, and the therapeutic effect is better than that of the FLC group administered alone. This shows that the combined use of compound B2 and FLC can reduce the fungal load in the kidneys of infected mice and reverse the drug resistance of resistant Candida albicans in mice.

[0209] Embodiment 32

[0210] Time-growth curve assay of preferred compound B2

[0211] The drug-resistant Candida albicans cells 0304103 in the late exponential growth phase were resuspended in RPMI1640 culture medium (5 mL) to a concentration of 1×10 5 cells / mL, and then add different doses of compound B2 and FLC to make FLC concentrations of 32, 16, and 8 μg / mL, and B2 concentrations of 32, 8, and 2 μg / mL. The effects of drugs alone or in combination on fungal growth were investigated. The samples were shaken and cultured at 30°C, and 100 μL of samples were taken at specific time points (0, 6, 12, 24, 36, and 48 h) and counted using a cell counting plate to calculate the fungal concentration in the sample at the current time point.

[0212] The logarithmic value of fungal concentration is plotted against time, such as Figure 2 As shown, Figure 2The figure is a schematic diagram of the growth curve of drug-resistant Candida albicans 0304103 under the combined action of different concentrations of compound B2 and FLC over time, where the ordinate is the logarithm of the fungal concentration. The experimental results show that the antifungal effect of compound B2 and FLC alone is basically non-existent, but the efficacy is significantly improved when the two are used in combination. When the concentration of compound B2 increases to 32 μg / mL, the combination of compound B2 and FLC completely inhibits the growth of fungi, and its synergistic effect is positively correlated with the concentration of compound B2. However, when the concentration of compound B2 is fixed to a fixed value, changing the concentration of FLC has no obvious effect on the growth of fungi. These results show that the synergistic effects of the two compounds are interdependent, among which compound B2 plays a leading role in the synergistic effect.

[0213] Embodiment 33

[0214] Effect of the preferred compound B2 on the biofilm formation of fungal virulence factors

[0215] The formation of biofilm is closely related to drug resistance, which protects fungi from immune attack. Therefore, the synergistic effect of compound B2 and FLC on the formation of drug-resistant Candida albicans biofilm was tested. The drug-resistant Candida albicans cells 0304103 in the late exponential growth period were resuspended in RPMI1640 culture medium (5 mL) to a concentration of 1×10 5 cells / mL. The bacterial suspension was inoculated in a 96-well culture plate, 100 μL per well. After culturing at 37°C for 90 min, the adhesion of fungal cells was completed. After the upper culture medium and non-adherent cells were aspirated, the adherent cells were gently washed with PBS and the PBS was aspirated. FLC was dissolved in RPMI1640 culture medium and prepared into drug-containing culture medium of different concentrations. The final concentration of FLC was 8, 16, 32, and 64 μg / mL. The drug-containing culture medium was inoculated in another blank 96-well plate, and the compound was added to the first column to make its concentration 64 μg / mL and then half-diluted. The final concentration of compound B2 was 0, 1, 2, 4, 8, 16, 32, and 64 μg / mL. The culture medium containing both compound B2 and FLC was transferred to the above-mentioned adherent cells, 100 μL per well, and incubated at 37°C for 24 h. The upper culture medium was aspirated, and the formed biofilm was detected by CCK8 method after being gently washed with PBS. The optical density at 450 nm (OD450) was measured using an enzyme-labeled instrument to calculate the biofilm formation rate.

[0216] The experimental results are as follows Figure 3 As shown, Figure 3 Schematic diagram of biofilm formation of drug-resistant Candida albicans 0304103 under the combined action of different concentrations of compound B2 and FLC. Figure 3In the figure, A is a schematic diagram of the effect of compound B2 alone on the biofilm formation of Candida albicans; Figure B is a schematic diagram of the effect of FLC alone on the biofilm formation of Candida albicans; Figures C–F are schematic diagrams of the effect of changing the concentration of compound B2 on the biofilm formation of Candida albicans when the concentrations of FLC are 8, 16, 32, and 64 μg / mL, respectively. It can be seen from the figure that even at high concentrations (64 μg / mL), compound B2 and FLC have no inhibitory effect on the formation of resistant Candida albicans 0304103 biofilm. However, when used in combination, a strong synergistic effect can be observed ( Figure 3 C–F). The inhibitory effect on biofilm formation was positively correlated with the concentration of compound B2 and was less affected by the change in FLC concentration, which was consistent with the results of the time-growth curve. At a higher concentration of FLC (32 μg / mL), the inhibitory effect of compound B2 (64 μg / mL) on biofilm formation could reach more than 80% ( Figure 3 (E) Therefore, the combination therapy can significantly inhibit the formation of drug-resistant Candida albicans biofilm.

[0217] Embodiment 34

[0218] Effect of the preferred compound B2 on fungal hyphae formation

[0219] Recent studies have shown that there are a variety of histone modifications in the morphological transformation of Candida albicans, especially histone acetylation and deacetylation. The dynamic morphogenesis from budding (yeast state) to hyphae state is crucial to the virulence of fungi. Therefore, the morphological effects of compound B2 and FLC on Candida albicans 0304103 after treatment alone or in combination were investigated. The drug-resistant Candida albicans 0304103 in the late exponential growth stage was resuspended in Spider medium at a concentration of 1×10 5 cells / mL. The bacterial suspension was transferred to a transparent 12-well plate, 1 mL per well. Different doses of compound B2 and FLC were then used alone or in combination, and the samples were divided into four groups, namely Control, B2 (32 μg / mL), FLC (32 μg / mL), and B2+FLC (32+32 μg / mL). After adding the compound, the fungal cells were cultured at 37°C for 2 h. The hyphae formation was observed using an inverted fluorescence microscope and photographed and recorded.

[0220] The results are as follows Figure 4 As shown, Figure 4Schematic diagram of the effect of compound B2 and FLC alone or in combination on the hyphae formation of drug-resistant Candida albicans 0304103. As can be seen from the figure, in the hyphae induction medium (Spider medium), when Candida albicans cells acted with FLC (32μg / mL) or compound B2 (32μg / mL) alone, a morphological transformation from yeast state to hyphae state can be observed. In contrast, in the synergistic treatment group of FLC and compound B2, only a large number of yeast-like fungal cells can be observed. Therefore, compound B2 can synergize with FLC to block the morphological transformation of fungi and reduce the invasion ability of Candida albicans.

[0221] Embodiment 35

[0222] The regulation of fungal resistance genes by the preferred compound B2

[0223] Fungal drug resistance is associated with upregulation of drug target proteins, increased drug efflux, and biofilm formation. Therefore, RT-qPCR was used to quantitatively analyze the effects of compound B2 alone or in combination with FLC on the expression of fungal drug resistance genes. Primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd. Resistant Candida albicans cells 0304103 were resuspended in YPD medium (30 mL) to a concentration of 1×10 7 cells / mL. Candida albicans cells were treated with DMSO, compound B2 (32 μg / mL), FLC (32 μg / mL), and the combined action of B2 and FLC. The samples were incubated at 35°C for 24 h, and the fungal cells collected by centrifugation were washed with PBS (3×5 mL). Fungal cells were collected and total RNA was extracted using the Fungal RNAout Kit (Jianshi Biotechnology) according to the operating instructions. Reverse transcription was performed according to the instructions of the kit (PrimeScript TM RTMaster Mix kit, TaKaRa), at 37°C for 15 min, 85°C for 5 s, and then cooled to 4°C. cDNA amplification was performed according to the following program: 1: 95°C, 30 s; 2: 95°C, 5 s, 40 cycles, 60°C, 34 s; 3: 95°C, 15 s, 60°C 60 s, 95°C 15 s. The threshold cycle was measured by monitoring fluorescence during the cycles using SYBR Green. ACT1 was used as the internal reference gene and 2 -ΔΔCt The fold changes of gene expression were analyzed by PCR.

[0224] The experimental results are as follows Figure 5 As shown, Figure 5The results are schematic diagrams of the effects of compound B2 alone or in combination on different drug resistance genes. In the figure, A is a schematic diagram of the expression changes of FLC drug target gene ERG11; B, C and D are schematic diagrams of the expression changes of efflux pump genes CDR1, MDR1 and CDR2 respectively; E and F are schematic diagrams of the expression changes of related genes GCA and ADH5 that regulate the production of extracellular matrix of fungal biofilms. It can be seen from the figure that ERG11 is the target gene of FLC, which is responsible for the expression of lanosterol 14α-demethylase; CDR and MDR encode multidrug exocytosis mediated by ATP binding cassette (ABC) and major superfamily (MSF), respectively. GCA1 and ADH5 are responsible for regulating the formation of extracellular matrix in fungal biofilms. ERG11 of drug-resistant Candida albicans cells is overexpressed under the action of FLC, but ERG11 is downregulated to below normal levels under the action of compound B2 alone or in combination with FLC. FLC alone upregulated the expression of efflux pump genes CDR1, CDR2, and MDR1, while compound B2 alone downregulated the expression, and the downregulation was more obvious in the compound B2 combined with FLC group ( Figure 5 For biofilm-related genes, FLC or compound B2 could downregulate the expression of GCA, and the synergistic effect of compound B2 and FLC was more significant ( Figure 5 Compound B2 alone or in combination with FLC can downregulate the expression of ADH5, while FLC alone has no effect on its expression ( Figure 5 F), indicating that compound B2 has the potential to reduce the extracellular matrix, allowing drugs to enter fungal cells more effectively. Quantitative analysis of the above genes confirmed that the combination of compound B2 and FLC can significantly reduce the expression of FLC target genes, multidrug efflux pump genes and biofilm-related genes, thereby improving drug efficacy and intracellular drug content.

[0225] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A compound having antifungal activity or a pharmaceutically acceptable salt thereof, characterized in that: The general structural formula is selected from one of the following structures: in: R 11 is selected from hydrogen and halogen; R 12 is selected from hydrogen and halogen; R 13 is selected from hydrogen and halogen; R 14 is selected from hydrogen and halogen; X is selected from R 15 Selected from hydrogen, halogen, C1-C10 alkyl; R 16 Selected from hydrogen, halogen, C1-C10 alkyl; R 17 Selected from hydrogen, halogen, C1-C10 alkyl; R 18 Selected from hydrogen, halogen, C1-C10 alkyl; R 19 Selected from hydrogen, halogen, C1-C10 alkyl; Y is selected from R 20 is selected from hydrogen and halogen; R 21 is selected from hydrogen and halogen; R 22 is selected from hydrogen and halogen; R 23 is selected from hydrogen and halogen; R 24 Selected from hydrogen and halogen.

2. The compound having antifungal activity or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: Among the compounds having antifungal activity, R 11 is selected from hydrogen, fluorine, chlorine and bromine; R 12 is selected from hydrogen, fluorine, chlorine and bromine; R 13 is selected from hydrogen, fluorine, chlorine and bromine; R 14 is selected from hydrogen, fluorine, chlorine and bromine; X is selected from R 15 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl; R 16 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl; R 17 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl; R 18 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl; R 19 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl; Y is selected from R 20 is selected from hydrogen, fluorine, chlorine and bromine; R 21 is selected from hydrogen, fluorine, chlorine and bromine; R 22 is selected from hydrogen, fluorine, chlorine and bromine; R 23 is selected from hydrogen, fluorine, chlorine and bromine; R 24 Selected from hydrogen, fluorine, chlorine, and bromine.

3. The compound having antifungal activity or a pharmaceutically acceptable salt thereof according to claim 2, characterized in that: The compound having antifungal activity is selected from one of the following structures:

4. Use of a compound having antifungal activity according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the preparation of an antifungal drug, wherein the fungus is selected from Cryptococcus neoformans and drug-resistant Candida albicans.

5. Use of the compound having antifungal activity according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in combination with fluconazole in the preparation of an antifungal drug, characterized in that: The fungus is selected from drug-resistant Candida albicans.